Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Compass Therapeutics (CMPX) Change in Accured Expenses (2023 - 2025)

Compass Therapeutics' Change in Accured Expenses history spans 3 years, with the latest figure at $2.7 million for Q4 2025.

  • For Q4 2025, Change in Accured Expenses fell 19.93% year-over-year to $2.7 million; the TTM value through Dec 2025 reached $5.1 million, up 35.06%, while the annual FY2025 figure was $5.1 million, 35.06% up from the prior year.
  • Change in Accured Expenses for Q4 2025 was $2.7 million at Compass Therapeutics, up from -$2.3 million in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $6.9 million in Q1 2025 and bottomed at -$4.3 million in Q3 2024.
  • The 3-year median for Change in Accured Expenses is -$1.6 million (2023), against an average of -$25583.3.
  • The largest YoY upside for Change in Accured Expenses was 1090.99% in 2025 against a maximum downside of 141.06% in 2025.
  • A 3-year view of Change in Accured Expenses shows it stood at -$3.1 million in 2023, then surged by 207.7% to $3.4 million in 2024, then decreased by 19.93% to $2.7 million in 2025.
  • Per Business Quant, the three most recent readings for CMPX's Change in Accured Expenses are $2.7 million (Q4 2025), -$2.3 million (Q3 2025), and -$2.2 million (Q2 2025).